Athira Pharma, Inc. SEC Filings

LeonaBio, Inc. has filed a resale registration covering up to 58,464,567 shares of common stock for potential sale by existing selling stockholders. These shares include stock already issued and shares issuable upon exercise of pre-funded warrants and common warrants that were originally sold in a December 2025 private placement. LeonaBio will not receive proceeds from any resale of shares by these holders, but could receive up to approximately $8,816 from cash exercise of 8,816,684 pre-funded warrants at $0.001 per share and approximately $146,249,987 from cash exercise of 23,031,494 common warrants at $6.35 per share. The company plans to use any such warrant exercise proceeds for working capital and to advance its drug pipeline, including lead candidates lasofoxifene and ATH-1105. Its common stock trades on Nasdaq under the symbol “LONA.”

Perceptive Advisors and its affiliates report a 19.99% beneficial stake in LeonaBio, Inc. common stock, totaling 1,859,322 shares. These shares are held through Perceptive Advisors LLC, its founder Joseph Edelman, Perceptive Life Sciences Master Fund, Ltd. and Perceptive Xontogeny Venture Fund II, LP, with the Master Fund holding 1,529,566 shares (16.4%) and PXV II holding 329,756 shares (3.5%).

The ownership percentages are based on 9,300,434 shares of LeonaBio common stock outstanding, which includes 3,943,887 shares outstanding as of November 5, 2025 and 5,356,547 shares issued in a private placement. The filing also notes a 19.99% beneficial ownership limitation: Joseph Edelman’s vested stock options and the warrants and pre-funded warrants held by the Master Fund and PXV II cannot be exercised to the extent such exercise would push the group’s beneficial ownership above 19.99%, and as of this amendment those warrants and pre-funded warrants are not exercisable under that limitation.

Athira Pharma, Inc. has changed its corporate identity to LeonaBio, Inc. Effective January 9, 2026, the company adopted the new name and updated its certificate of incorporation and bylaws accordingly, without requiring stockholder approval and without changing stockholder rights.

The company will begin trading on the Nasdaq Capital Market under the new ticker symbol “LONA” at market open on January 12, 2026, with no CUSIP change or required action by stockholders. LeonaBio also launched a new corporate website at www.leonabio.com, which will host investor materials and governance documents.

Separately, the company entered into an amended and restated change in control and severance agreement with Chief Financial Officer Robert Renninger, providing specified cash severance, COBRA benefits and accelerated vesting of service-based equity upon certain terminations, and increased his annual base salary to $460,000, effective retroactively as of December 16, 2025.

Athira Pharma, Inc. received an amended Schedule 13G reporting updated passive ownership by Acorn-affiliated investment entities and Anders Hove in its common stock.

Acorn Bioventures, L.P. and Acorn Capital Advisors GP, LLC each report beneficial ownership of 250,348 shares, or 2.6% of Athira’s common stock. Acorn Bioventures 2, L.P. and Acorn Capital Advisors GP 2, LLC each report 345,720 shares, or 3.6% of the class. Anders Hove, as manager of both general partners, reports beneficial ownership of 596,068 shares, representing 6.2% of Athira’s common stock.

The percentages are based on 9,604,313 shares outstanding as of November 18, 2025, as cited in an Athira announcement. The filing is certified as a passive investment under the 13G standard, stating the securities are not held for the purpose of changing or influencing control of Athira Pharma.

Athira Pharma amended a recent report to add exhibit hyperlinks and detailed two major transactions that reshape its pipeline and funding. The company agreed to a $90 million PIPE private placement, issuing common stock, pre-funded warrants, and short-dated Series A and B warrants, with Cantor as placement agent. Net proceeds are earmarked for working capital, primarily to advance lasofoxifene and ATH-1105, and are expected to extend the company’s cash runway into 2028.

Athira also executed the Sermonix Transaction, licensing global (ex-Asia/Middle East) rights to lasofoxifene and entering a parallel license with Ligand. Upfront consideration includes about $34.9 million in equity to Sermonix, roughly $16.8 million of assumed third‑party obligations, monthly payments creditable against future milestones, and potential milestones up to $100 million plus royalties. Sermonix receives a pre-funded warrant for 5,502,402 shares, subject to stockholder approval mechanics and a capped cash redemption right. Athira updates its strategy to focus on late-stage lasofoxifene in ESR1‑mutated metastatic breast cancer and ATH‑1105 in ALS.

Athira Pharma is raising new capital and reshaping its pipeline around oncology and ALS. The company entered into a private placement with institutional investors to sell 5,356,547 common shares and pre-funded and common warrants linked to additional shares at a purchase price of $6.35–$6.349 per share or pre-funded warrant, for expected gross proceeds of about $90 million before fees. Certain investors, including Perceptive-related funds, are participating, and two large investors gain the right to designate Board members while two current directors are expected to resign within six months of closing.

Athira simultaneously signed licensing deals with Sermonix and Ligand for oral lasofoxifene outside Asia and parts of the Middle East, assuming the global Phase 3 ELAINE‑3 trial and related manufacturing and service contracts. Consideration includes approximately $34.9 million in equity via a 5,502,402‑share pre‑funded warrant, monthly payments, and up to $100 million in milestones to Sermonix plus milestone and royalty obligations to Ligand. As of September 30, 2025, Athira had $25.2 million in cash, cash equivalents and investments and now expects, with private placement proceeds, to fund development of lasofoxifene and ALS candidate ATH‑1105 into 2028.

Athira Pharma (ATHA) filed its Q3 2025 10‑Q reporting narrower losses and a streamlined cost base. Net loss was $6.6 million for the quarter, a sharp improvement from $28.7 million a year ago, as research and development and general and administrative expenses declined. Other income contributed modestly.

Cash, cash equivalents and investments were $25.2 million as of September 30, 2025. Management states this balance is sufficient to fund operating expenses and capital needs for at least the next 12 months, and the company maintains a $75.0 million at‑the‑market equity facility with Cantor Fitzgerald and BTIG, with no sales to date.

The company effected a 1‑for‑10 reverse stock split on September 17, 2025 and subsequently regained Nasdaq minimum bid compliance on October 2, 2025. Athira has paused fosgonimeton development and is focusing on ATH‑1105 for ALS; a completed Phase 1 in healthy volunteers showed a favorable safety profile. Shares outstanding were 3,943,887 as of November 5, 2025.

Athira Pharma (ATHA)

The company notes that information under Items 2.02 and 7.01, and Exhibit 99.1, is furnished and not deemed filed under the Exchange Act. Athira also highlights its disclosure channels, including its website, investor site, and social media accounts on X (@athirapharma), LinkedIn, Instagram (@athirapharma), and Facebook.